HYLOMORPH closes CHF 3.2 millions Series A funding
25-09-2018 – HYLOMORPH, an ETH Zurich spin-off and Medtech startup, closes its Series A financing round with CHF 3.2 million.
The funding will allow the startup company to finalize product development and conduct clinical studies required for FDA approval and CE certification expected in 2021.
